Cerebrolysin 30MG

Cerebrolysin is a hydrolyzate derived from bovine brain tissue and is intended for use in research applications. This product is provided in a 30mg concentration, formulated to support neuropharmacological and neuroprotective investigations.

Research Context

Cerebrolysin has been extensively studied in preclinical research settings as a potential therapeutic agent in neuroprotective and regenerative contexts. Its formulation includes a mixture of biologically active peptides and low molecular weight compounds extracted from bovine brain tissue. The peptide mixture has been investigated for its potential effects on neurogenesis, synaptic plasticity, and the mitigation of neurodegenerative processes.

Research Overview

Cerebrolysin was originally developed in Italy and has been used in academic and industrial research settings for decades. Its preparation involves enzymatic hydrolysis of bovine brain tissue, resulting in a complex mixture of peptides that can exhibit diverse biological activities. Preclinical research has focused on evaluating its effects in models of ischemic stroke, Alzheimer’s disease, Parkinson’s disease, traumatic brain injury, and aging-related cognitive decline.

Key Research Focus Areas

• Neuroprotective Effects in Ischemic Stroke Models
• Enhancement of Neurogenesis and Synaptic Plasticity
• Mitigation of Neurodegenerative Pathologies
• Cognitive Function Support in Aging Research
• Investigations in Traumatic Brain Injury Models

Safety and Compliance Notice

This product is intended solely for research purposes under the guidance of qualified professionals. Cerebrolysin 30MG should only be utilized in accordance with approved institutional protocols and regulatory requirements. The formulation does not claim therapeutic, diagnostic, or cosmetic benefits and is not intended for human or animal consumption.

Important Disclaimer

For research use only. Not for human or animal consumption.